Skip to main content

AddLife AB (publ) (ADDLF)

New York Stock Exchange Healthcare Medical - Instruments & SuppliesView data quality →
56.7Fair

ValueMarkers Composite Index

Top 62%#17,049 of 44,714
Overvalued

647% above intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
8/9
Strong
Beneish
-2.87
Low Risk
Altman
1.77
Distress
DCF Value
$1
Overvalued
ROIC
5.4%
Low
P/E
34.0
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

AddLife AB (publ) (ADDLF) — VMCI valuation read

The headline on AddLife AB (publ) (ADDLF) is a 57/100 VMCI score, set against a Healthcare sector median of 50. That 7-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

ADDLF insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** ADDLF trades at 23.0x earnings, 28% above the Healthcare median of 18.0x sets the value side. ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of 2.7x is the rate-sensitivity line to watch sets the risk side, the three lines a value buyer reads first on ADDLF.

ADDLF fell 1.3% over the trailing 7 days, with a -12.8% read on a 30-day basis.

AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments. This segment also offers support, maintenance, advice, and training services. The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.

CEO: Fredrik Dalborg2,251 employeesSEwww.add.life

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in ADDLF’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.